This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Eldepryl

Mylan Inc.

Drug Names(s): selegiline hydrochloride

Description: Eldepryl is a selective, irreversible monoamine oxidase type-B (MAO-B) inhibitor that blocks the breakdown of dopamine, a substance in the brain needed to facilitate movement.

Deal Structure: Eldepryl was marketed by Somerset Pharmaceuticals, a collaboration between Watson and Mylan. In July 2008, Mylan acquired Watson's 50 percent interest in Somerset, making the proprietary research and development company a wholly-owned subsidiary of Mylan.

In July 2011, Eisai Co. announced that it has entered into a comprehensive marketing agreement with Orion Corporation concerning Fareston and Eldepryl. Under the terms of the agreement, Eisai shall acquire from Orion the exclusive rights to market the two products in China, and will distribute them through its Chinese subsidiary Eisai China. Both drugs were previously marketed in China by a local distributor, however, marketing rights were transferred to Eisai China following the expiration of the contract between the distributor and Orion in early June 2011.

Teva and Mylan
In April 2015, Teva proposed to acquire all of the outstanding shares of Mylan in a transaction valued at $82.00 per Mylan share, with the...See full deal structure in Biomedtracker

Partners: Orion Corporation


Eldepryl News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug